EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Expected impact of MRI-targeted biopsy interreader variability among uropathologists on ProScreen prostate cancer screening trial: a pre-trial validation study

Ronja Hietikko, Tuomas Mirtti, Tuomas P Kilpeläinen, Teemu Tolonen, Anne Räisänen-Sokolowski, Stig Nordling, Jill Hannus, Marita Laurila, Kimmo Taari, Teuvo L J Tammela, Reija Autio, Kari Natunen und 2 weitere

World Journal of Urology · 2024

DOI: 10.1007/s00345-024-04898-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift World Journal of Urology, 2024. Verfasst von Ronja Hietikko und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. Ronja.hietikko@hus.fi. Hauptthemen laut MEDLINE: Prostatic Neoplasms. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Syöpäsäätiö, Terveyden Tutkimuksen Toimikunta, Helsingin Yliopisto.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Prostate cancer (PCa) histology, particularly the Gleason score, is an independent prognostic predictor in PCa. Little is known about the inter-reader variability in grading of targeted prostate biopsy based on magnetic resonance imaging (MRI). The aim of this study was to assess inter-reader variability in Gleason grading of MRI-targeted biopsy among uropathologists and its potential impact on a population-based randomized PCa screening trial (ProScreen).

Methods

From June 2014 to May 2018, 100 men with clinically suspected PCa were retrospectively selected. All men underwent prostate MRI and 86 underwent targeted prostate of the prostate. Six pathologists individually reviewed the pathology slides of the prostate biopsies. The five-tier ISUP (The International Society of Urological Pathology) grade grouping (GG) system was used. Fleiss’ weighted kappa ( κ ) and Model-based kappa for associations were computed to estimate the combined agreement between individual pathologists.

Results

GG reporting of targeted prostate was highly consistent among the trial pathologists. Inter-reader agreement for cancer (GG1–5) vs. benign was excellent (Model-based kappa 0.90, Fleiss’ kappa κ = 0.90) and for clinically significant prostate cancer (csPCa) (GG2–5 vs. GG0 vs. GG1), it was good (Model-based kappa 0.70, Fleiss’ kappa κ 0.67).

Conclusions

Inter-reader agreement in grading of MRI-targeted biopsy was good to excellent, while it was fair to moderate for MRI in the same cohort, as previously shown. Importantly, there was wide consensus by pathologists in assigning the contemporary GG on MRI-targeted biopsy suggesting high reproducibility of pathology reporting in the ProScreen trial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsMaleHumansEarly Detection of CancerReproducibility of ResultsRetrospective StudiesProstate-Specific AntigenBiopsyMagnetic Resonance ImagingNeoplasm GradingImage-Guided Biopsy

Stichwörter der Autor:innen

AgreementGradingInterobserverKappaPathology

Substanzen

Prostate-Specific Antigen

Autor:innen und Institutionen

  • Department of Urology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. Ronja.hietikko@hus.fi.
  • Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland. Ronja.hietikko@hus.fi.
  • Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • HUS Diagnostic Center, Department of Pathology, HUS Helsinki University Hospital, Helsinki, Finland.
  • Department of Urology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
  • Fimlab Laboratories, Department of Pathology, Tampere University Hospital, Tampere, Finland.

Förderung

  • Syöpäsäätiö
  • Terveyden Tutkimuksen Toimikunta
  • Helsingin Yliopisto
  • University of Helsinki

Zitieren

APA

Hietikko, R., Mirtti, T., Kilpeläinen, T. P., Tolonen, T., Räisänen-Sokolowski, A., Nordling, S., Hannus, J., Laurila, M., Taari, K., Tammela, T. L. J., Autio, R., Natunen, K., Auvinen, A., & Rannikko, A. (2024). Expected impact of MRI-targeted biopsy interreader variability among uropathologists on ProScreen prostate cancer screening trial: a pre-trial validation study. World Journal of Urology. https://doi.org/10.1007/s00345-024-04898-2

Vancouver

Hietikko R, Mirtti T, Kilpeläinen TP, Tolonen T, Räisänen-Sokolowski A, Nordling S, et al. Expected impact of MRI-targeted biopsy interreader variability among uropathologists on ProScreen prostate cancer screening trial: a pre-trial validation study. World Journal of Urology. 2024. doi:10.1007/s00345-024-04898-2

BibTeX
@article{Hietikko2024,
  author = {Hietikko, Ronja and Mirtti, Tuomas and Kilpeläinen, Tuomas P and Tolonen, Teemu and Räisänen-Sokolowski, Anne and Nordling, Stig and Hannus, Jill and Laurila, Marita and Taari, Kimmo and Tammela, Teuvo L J and Autio, Reija and Natunen, Kari and Auvinen, Anssi and Rannikko, Antti},
  title = {Expected impact of MRI-targeted biopsy interreader variability among uropathologists on ProScreen prostate cancer screening trial: a pre-trial validation study},
  journal = {World Journal of Urology},
  year = {2024},
  doi = {10.1007/s00345-024-04898-2}
}
Kostenlos starten →